TITLE

Cydan Accelerator Using $16M To Boost Orphan Drug Players

AUTHOR(S)
Osborne, Randy
PUB. DATE
April 2013
SOURCE
BioWorld Today;4/11/2013, Vol. 24 Issue 69, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the expansion plan of orphan drug accelerator Cydan LLC to set-up five new companies for orphan drug development in four years. It notes that the plan receives funding of $16 million from its investors. Cydan is hoping to conduct projects concentrating on de-risking experiments between six and 18 months.
ACCESSION #
87637991

 

Related Articles

  • Incentives to Innovate.  // BioWorld Insight;4/16/2012, Vol. 20 Issue 16, p4 

    The article provides information related to the encouragement for the development of orphan drugs for diseases that had no treatment.

  • Orphan Drug Status. S. H. // Pharmaceutical Executive;May2006, Vol. 26 Issue 5, p22 

    The article reports on the findings of a research, published in the March 2006 issue of the "British Journal of Clinical Pharmacology," which showed that orphan drug development in Europe is much slower than in the United States. According to the article, orphan drugs are used to treat rare...

  • FDA Drug Approvals. Pipeline preview.  // Formulary;Mar2012, Vol. 47 Issue 3, p87 

    The article reports on drugs, including cinryze, menveo and denosumab, which have been evaluated in 2012 by the U.S. Food and Drug Administration and have received complete responses, were not recommended for approval or received orphan drug designations. Drugs which were given a priority review...

  • Orphan drugs new kid on the block for pharma?  // PharmacoEconomics & Outcomes News;4/17/2010, Issue 601, p3 

    The article discusses the findings of a research on the relevance of orphan drug development to the pharmaceutical industry.

  • ORPHANS IN DANGER. Saltonstall, Peter // Medical Marketing & Media;Apr2014, Vol. 49 Issue 4, p44 

    The article discusses the research, educational and policy challenges facing patient advocacy community when it comes to orphan drug development for the treatment rare diseases.

  • FDA Drug Approvals. Pipeline preview.  // Formulary;Aug2011, Vol. 46 Issue 8, p293 

    The article gives brief information about drugs and the approval process of the U.S. Food and Drug Administration (FDA), including on Zolpidem tartrate sublingual tablet, used to treat insomnia, Brentuximab vedotin, used to treat Hodgkin lymphoma relapse, and the Golimumab supplemental Biologics...

  • FDA Drug Approvals. Pipeline preview.  // Formulary;Nov2011, Vol. 46 Issue 11, p455 

    The article reports on drugs which were rejected for approval, were not recommended for approval, were given fast track designation and given orphan drug designation by the U.S. Food and Drug Administration in 2011.

  • FDA Drug Approvals. Pipeline preview.  // Formulary;Oct2011, Vol. 46 Issue 10, p400 

    The article reports on responses which the U.S. Food & Drug Administration has given to applications for approval for several drugs, including Golimumab, a meningococcal and Hib combination vaccine, and Desvenlafaxine. A discussion of drugs which the agency has approved, is reviewing, has given...

  • FDA Drug Approvals. Pipeline review.  // Formulary;Feb2012, Vol. 47 Issue 2, p45 

    The article reports on drugs, including dapagliflozin, progesterone, and porfimer sodium, that were evaluated by the U.S. Food and Drug Administration in 2012 and either received a complete response, were not recommended for approval, or received fast track designation from the agency. Drugs...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics